Probiotics in Crohn's disease remission: a systematic review
DOI:
https://doi.org/10.37527/2022.72.1.006Palabras clave:
Crohn Disease, Ulcerative Colitis, Intestinal Mucosa, Probiotics, Enfermedad de Crohn, Colitis Ulcerativa, Mucosa Intestinal, ProbióticosResumen
Crohn's disease (CD) is an inflammatory condition that can affect the entire gastrointestinal tract due to an exacerbated and inadequate immune system response. Objective. This study aimed to conduct a systematic review, through clinical trials, about the use of probiotics in humans with CD. Materials and methods. Research was carried out in the PubMed, Scopus and Science Direct databases using the keywords “Crohn's disease” and “probiotics”. We conducted the review by searching clinical trials published from 2000 to December 2019. Results. Of 2,164 articles found, only nine were considered eligible for this review. The studies investigated patients with CD at different stages of the pathology, and in three studies the potential effect of probiotics in the active phase was observed; in two, in the remission phase; and in four, after intestinal surgery. The sample size of the studies ranged from 11 to 165 individuals and the age of the participants between 5 and 71 years. Gram-positive bacteria were used in six clinical interventions and in two studies yeasts were used. As for the significant results obtained with the treatment with probiotics, in one study there was beneficial clinical effects in patients and, in another, there was an improvement in intestinal permeability. Conclusion. Currently, it is not possible to establish a recommendation for probiotic therapy to control CD due to the few clinical trials with significant results. There is a need for more research on clinical intervention with probiotics in CD to clarify the action, define doses and time of use.
La enfermedad de Crohn (EC) es una afección inflamatoria que puede afectar todo el tracto gastrointestinal debido a una respuesta del sistema inmunitario exacerbada e inadecuada. Objetivo. Realizar una revisión sistemática, a través de ensayos clínicos, sobre el uso de probióticos en humanos con EC. Materiales y métodos. La investigación se realizó en las bases de datos PubMed, Scopus y Science Direct utilizando las palabras clave “enfermedad de Crohn” y “probióticos”. La revisión se hizo en ensayos clínicos publicados desde 2000 hasta diciembre 2019. Resultados. De 2164 artículos encontrados, solo nueve fueron considerados elegibles. Los estudios investigaron pacientes con EC en diferentes etapas de la patología, y en tres estudios se observó el efecto potencial de los probióticos en la fase activa; en dos, en remisión; y en cuatro, tras cirugía intestinal. El tamaño de la muestra fue entre 11 y 165 individuos y la edad entre 5 y 71 años. Se utilizaron bacterias grampositivas en seis intervenciones clínicas y en dos estudios se utilizaron levaduras. En cuanto a los resultados significativos obtenidos con el tratamiento con probióticos, en un estudio hubo efectos clínicos beneficiosos en los pacientes y, en otro, hubo una mejora en la permeabilidad intestinal. Conclusión. Actualmente, no es posible establecer una recomendación de terapia con probióticos para el control de la EC debido a los pocos ensayos clínicos con resultados significativos. Existe la necesidad de más investigación sobre la intervención clínica con probióticos en EC para aclarar la acción, definir dosis y tiempo de uso.
Descargas
Citas
Veauthier B, Hornecker JR. Crohn's Disease: Diagnosis and Management. Am Fam Physician. 2018;98(11):661-669.
Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. World wideincidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-basedstudies. Lancet 2017;390(10114):2769-78. Available in: http://doi.org/10.1016/S0140-6736(17)32448-0.
Quaresma AB, Kaplan GG , Kotze PG. The globalization of inflammatory bowel disease: the incidence and prevalence of inflammatory bowel disease in Brazil. Curr Opin Gastroenterol 2019, 35:259-264. Available in: http://doi.org/10.1097/MOG.0000000000000534.
Victoria CR, Sassak LY, Nunes HRC. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. Arq. Gastroenterol. [online]. 2009;46(1):20-25. Available in: https://doi.org/10.1590/S0004-28032009000100009.
Gasparini RG, Sassaki LY, Saad-Hossne R. Inflammatory bowel disease epidemiology in São Paulo State, Brazil. Clin Exp Gastroenterol 2018; 11:423-429. Available in: http://doi.org/10.2147/CEG.S176583.
Crowley E, Muise A. Inflammatory Bowel Disease: What Very Early Onset Disease Teaches Us. Gastroenterol Clin North Am. 2018;47(4):755-772. Available in: http://doi: 10.1016/j.gtc.2018.07.004.
Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology 2019;157:647-659.
Barbosa BA. Fatores ambientais associados ao desenvolvimento de Doença Inflamatória Intestinal [dissertação]. Porto: Universidade do Porto, Instituto de Ciências Biomédicas Abel Salazar, Mestrado Integrado em Medicina; 2015-2016. 34 p.
Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, et al. Pathophysiology of Crohn's disease inflammation and recurrence. Biol Direct. 2020;15(1):23. Available in: https://doi.org/10.1186/s13062-020-00280-5.
Wieërs G, Belkhir L, Enaud R, Leclercq S, Philippart de Foy JM, Dequenne I, et al.. How Probiotics Affect the Microbiota. Front Cell Infect Microbiol. 2020;9:454. Available in: https://doi.org/10.3389/fcimb.2019.00454.
Bourreille A, Guillaume C, Girad LD, David L, Laurent B, Jean Louis D, et al.Saccharomyces boulardii does not prevent relapse of Crohn’s disease. Clin Gastroenterol Hepatol. 2013;11:982-7.
Bousvaros A, Guadalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, et al. A Randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis. 2005;11(9):833-9.
Marteau P, Lémann M, Seksik P, Laharie D, Colombel JF, Bouhnik Y, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55(6): 842–7.
Van Gossum A, Dewit O, Louis E, Hertogh G, Baert F, Fontaine F, et al. Multicenter randomized- controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileo-cecal resection. Inflamm Bowel Dis. 2007;13(2):135-42.
Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin Gastroenterol Hepatol 2015;13(5):928-35.e2.
Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gatroenterol. 2004;4:5.Available in: https://doi.org/10.1186/1471-230X-4-5.
Vilela EG, Ferrari MLA, Torres HOG, Pinto AG, Aguirre ACC, Martins FP, et al. Influence of Saccharomyces boulardii of the intestinal permeability of patients with Crohn’s disease in remission. Scand J Gastroenterol. 2008;43(7):842-8.
Guslandi M.; Mezzi G.; Sorghi M.; Testoni P. A. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci. 2000;45(7):1462-4.
Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51(3): 405-9.
Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn’s disease. Dis Mon. 2018;64(2):20-57.
Ahmed W, Rashid S. Functional and therapeutic potential of inulin: A comprehensive review. Crit Rev Food Sci Nutr. 2019;59(1):1-13. Available in: https://doi.org/10.1080/10408398.2017.1355775.
Oh GM, Moon W, Seo KI, Jung K, Kim JH, Kim SE, et al. Changes in the Crohn's Disease Activity Index and Safety of Administering Saccharomyces Boulardii in Patients with Crohn's Disease in Clinical Remission: A Single Hospital-based Retrospective Cohort Study. Korean J Gastroenterol. 2020;76(6):314-21. Available in: . PMID: 33250507.
Ataliba,GS. Avaliação da influência na barreira intestinal, por meio do teste de permeabilidade e dosagem de calprotectina fecal, em pacientes com doença de crohn, em resposta ao tratamento com terapia biológica (anticorpos anti-tnf alfa) [dissertação]. Belo Horizonte: Universidade Federal de Minas Gerais, Programa de PósGraduação em Ciências Aplicadas à Saúde do Adulto, área de concentração Ciências Aplicadas ao Aparelho Digestivo, Faculdade de Medicina; 2015. 73 p.
Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68(Suppl 3):s1-s106. Available in: https://doi.org/10.1136/gutjnl-2019-318484.
Shang Q. From correlation to causation: The missing point in the study of functional foods and gut microbiota. J Funct Foods. 2019;61: 103466. Available in: https://doi.org/10.1016/j.jff.2019.103466
Reddavide R, Rotolo O, Caruso MG, Stasi E, Notarnicola M, Miraglia C, Nouvenne A, Meschi T, De' Angelis GL, Di Mario F, Leandro G. The role of diet in the prevention and treatment of Inflammatory Bowel Diseases. Acta Biomed. 2018;89(9-S):60-75. Available in: https://doi.org/ 10.23750/abm.v89i9-S.7952.
Forbes A, Escher J, Hébuterne X, Klek S, Krznaric Z, Schneider S, et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr. 2017;36(2):321-47.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Archivos Latinoamericanos de Nutrición (ALAN)
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato
Adaptar — remezclar, transformar y construir a partir del material
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
